To Improve the Clinical Outcome of Ultrasound-guided Radiofrequency Ablation by NAVIRFA® Navigation System.
- Conditions
- Radiofrequency Ablation
- Interventions
- Device: NAVIRFA® Navigation SystemDevice: ultrasound
- Registration Number
- NCT05818176
- Lead Sponsor
- National Taiwan University Hospital
- Brief Summary
Ultrasonic-guided radiofrequency ablation is the most common minimally invasive treatment for liver cancer. This study will use my country's self-developed intelligent ultrasonic navigation tool (NAVIRFA® Navigation System) to assist in the puncture of the needle during ablation, to observe the operation time, Whether the needle accuracy, ablation effect and complications are different from the traditional free-hand ultrasonic guidance technology.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Patients with malignant liver tumors less than three centimeters in size who are expected to suffer radiofrequency tumor ablation in the hospital.
- At least 20 years old.
- Patients with abnormal coagulation function and low platelets are not suitable for ablation therapy after evaluation by the trial host.
- Those who are unable to accept computerized tomography and MRI examinations, such as poor renal function or contrast agent allergy, are not suitable for examination after the evaluation of the test host.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NAVIRFA® Navigation System NAVIRFA® Navigation System - ultrasound-guided ultrasound -
- Primary Outcome Measures
Name Time Method required scan time Before ablation treatment the time required until start of the ablation (measured from the time of the first US scan to the start of the ablation).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
National Taiwan University Hospital
🇨🇳Taipei, Taiwan, Taiwan